IPILIMUMAB EXPANDED ACCESS PROGRAMME (EAP): 0% OF CLINICAL BENEFIT IN EVALUABLE ADVANCED MELANOMA PATIENTS
IPILIMUMAB EXPANDED ACCESS PROGRAMME (EAP): 0% OF CLINICAL BENEFIT IN EVALUABLE ADVANCED MELANOMA PATIENTS. Stefania V.L. Nicoletti, Massimo Guidoboni, Laura Ridolfi,Alberto Farolfi, Alessandro, Passardi, Linda Valmorri, Angela Ragazzini, Ruggero Ridolfi… Continue reading